Cargando…
A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
Solid Organ Transplant (SOT) recipients are at significant higher risk for COVID-19 and due to immunosuppressive medication, the immunogenicity after vaccination is suboptimal. In the previous studies, booster method showed significant benefit in this population. In the current study, we compared us...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113439/ https://www.ncbi.nlm.nih.gov/pubmed/37091963 http://dx.doi.org/10.3389/ti.2023.10938 |
_version_ | 1785027837205413888 |
---|---|
author | Natori, Yoichiro Martin, Eric Mattiazzi, Adela Arosemena, Leopoldo Ortigosa-Goggins, Mariella Shobana, Sivan Roth, David Kupin, Warren Lee Burke, George William Ciancio, Gaetano Morsi, Mahmoud Phancao, Anita Munagala, Mrudula R. Butrous, Hoda Manickavel, Suresh Sinha, Neeraj Sota, Katherine Pallikkuth, Suresh Bini, Julia Simkins, Jacques Anjan, Shweta Vianna, Rodrigo M. Guerra, Giselle |
author_facet | Natori, Yoichiro Martin, Eric Mattiazzi, Adela Arosemena, Leopoldo Ortigosa-Goggins, Mariella Shobana, Sivan Roth, David Kupin, Warren Lee Burke, George William Ciancio, Gaetano Morsi, Mahmoud Phancao, Anita Munagala, Mrudula R. Butrous, Hoda Manickavel, Suresh Sinha, Neeraj Sota, Katherine Pallikkuth, Suresh Bini, Julia Simkins, Jacques Anjan, Shweta Vianna, Rodrigo M. Guerra, Giselle |
author_sort | Natori, Yoichiro |
collection | PubMed |
description | Solid Organ Transplant (SOT) recipients are at significant higher risk for COVID-19 and due to immunosuppressive medication, the immunogenicity after vaccination is suboptimal. In the previous studies, booster method showed significant benefit in this population. In the current study, we compared using a mix-and-match method vs. same vaccine as a third dose in SOT recipients. This was a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs. JNJ-78436735 vaccine as the third dose after two doses of BNT162b2 vaccine. We included adult SOT recipients with functional graft who had received two doses of BNT162b2 vaccine. Participants were randomly assigned to receive either BNT162b2 or JNJ-78436735 in one-to-one ratio. Primary outcome was SARS-CoV-2 IgG positivity at 1 month after the third dose. Sixty SOT recipients, including 36 kidney, 12 liver, 2 lung, 3 heart, and 5 combined transplants, were enrolled, and 57 recipients were analyzed per protocol. There were no statistically significant differences between the two vaccine protocols for IgG positivity (83.3% vs. 85.2% for BNT162b2 and JNJ-78436735, respectively, p = 0.85, Odds Ratio 0.95, 95% Confidence Interval 0.23–4.00). Comparison of the geometric mean titer demonstrated a higher trend with BNT162b2 (p = 0.09). In this pilot randomized controlled trial comparing mix and match method vs. uniform vaccination in SOT recipients, both vaccines were safely used. Since this was a small sample sized study, there was no statistically significant difference in immunogenicity; though, the mix and match method showed relatively lower geometric mean titer, as compared to uniform vaccine. Further studies need to be conducted to determine duration of this immunogenicity. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT05047640?term=20210641&draw=2&rank=1, identifier 20210641. |
format | Online Article Text |
id | pubmed-10113439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101134392023-04-20 A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients Natori, Yoichiro Martin, Eric Mattiazzi, Adela Arosemena, Leopoldo Ortigosa-Goggins, Mariella Shobana, Sivan Roth, David Kupin, Warren Lee Burke, George William Ciancio, Gaetano Morsi, Mahmoud Phancao, Anita Munagala, Mrudula R. Butrous, Hoda Manickavel, Suresh Sinha, Neeraj Sota, Katherine Pallikkuth, Suresh Bini, Julia Simkins, Jacques Anjan, Shweta Vianna, Rodrigo M. Guerra, Giselle Transpl Int Health Archive Solid Organ Transplant (SOT) recipients are at significant higher risk for COVID-19 and due to immunosuppressive medication, the immunogenicity after vaccination is suboptimal. In the previous studies, booster method showed significant benefit in this population. In the current study, we compared using a mix-and-match method vs. same vaccine as a third dose in SOT recipients. This was a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs. JNJ-78436735 vaccine as the third dose after two doses of BNT162b2 vaccine. We included adult SOT recipients with functional graft who had received two doses of BNT162b2 vaccine. Participants were randomly assigned to receive either BNT162b2 or JNJ-78436735 in one-to-one ratio. Primary outcome was SARS-CoV-2 IgG positivity at 1 month after the third dose. Sixty SOT recipients, including 36 kidney, 12 liver, 2 lung, 3 heart, and 5 combined transplants, were enrolled, and 57 recipients were analyzed per protocol. There were no statistically significant differences between the two vaccine protocols for IgG positivity (83.3% vs. 85.2% for BNT162b2 and JNJ-78436735, respectively, p = 0.85, Odds Ratio 0.95, 95% Confidence Interval 0.23–4.00). Comparison of the geometric mean titer demonstrated a higher trend with BNT162b2 (p = 0.09). In this pilot randomized controlled trial comparing mix and match method vs. uniform vaccination in SOT recipients, both vaccines were safely used. Since this was a small sample sized study, there was no statistically significant difference in immunogenicity; though, the mix and match method showed relatively lower geometric mean titer, as compared to uniform vaccine. Further studies need to be conducted to determine duration of this immunogenicity. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT05047640?term=20210641&draw=2&rank=1, identifier 20210641. Frontiers Media S.A. 2023-04-05 /pmc/articles/PMC10113439/ /pubmed/37091963 http://dx.doi.org/10.3389/ti.2023.10938 Text en Copyright © 2023 Natori, Martin, Mattiazzi, Arosemena, Ortigosa-Goggins, Shobana, Roth, Kupin, Burke, Ciancio, Morsi, Phancao, Munagala, Butrous, Manickavel, Sinha, Sota, Pallikkuth, Bini, Simkins, Anjan, Vianna and Guerra. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Health Archive Natori, Yoichiro Martin, Eric Mattiazzi, Adela Arosemena, Leopoldo Ortigosa-Goggins, Mariella Shobana, Sivan Roth, David Kupin, Warren Lee Burke, George William Ciancio, Gaetano Morsi, Mahmoud Phancao, Anita Munagala, Mrudula R. Butrous, Hoda Manickavel, Suresh Sinha, Neeraj Sota, Katherine Pallikkuth, Suresh Bini, Julia Simkins, Jacques Anjan, Shweta Vianna, Rodrigo M. Guerra, Giselle A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients |
title | A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients |
title_full | A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients |
title_fullStr | A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients |
title_full_unstemmed | A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients |
title_short | A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients |
title_sort | pilot single-blinded, randomized, controlled trial comparing bnt162b2 vs. jnj-78436735 vaccine as the third dose after two doses of bnt162b2 vaccine in solid organ transplant recipients |
topic | Health Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113439/ https://www.ncbi.nlm.nih.gov/pubmed/37091963 http://dx.doi.org/10.3389/ti.2023.10938 |
work_keys_str_mv | AT natoriyoichiro apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT martineric apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT mattiazziadela apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT arosemenaleopoldo apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT ortigosagogginsmariella apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT shobanasivan apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT rothdavid apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT kupinwarrenlee apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT burkegeorgewilliam apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT cianciogaetano apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT morsimahmoud apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT phancaoanita apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT munagalamrudular apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT butroushoda apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT manickavelsuresh apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT sinhaneeraj apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT sotakatherine apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT pallikkuthsuresh apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT binijulia apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT simkinsjacques apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT anjanshweta apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT viannarodrigom apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT guerragiselle apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT natoriyoichiro pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT martineric pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT mattiazziadela pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT arosemenaleopoldo pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT ortigosagogginsmariella pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT shobanasivan pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT rothdavid pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT kupinwarrenlee pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT burkegeorgewilliam pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT cianciogaetano pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT morsimahmoud pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT phancaoanita pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT munagalamrudular pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT butroushoda pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT manickavelsuresh pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT sinhaneeraj pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT sotakatherine pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT pallikkuthsuresh pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT binijulia pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT simkinsjacques pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT anjanshweta pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT viannarodrigom pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients AT guerragiselle pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients |